Bayer gets FDA approval for prostate cancer drug Nubeqa

This article was originally published here

The approval was based on data from the phase III ARAMIS trial, which assessed Nubeqa plus androgen deprivation therapy (ADT). According to the company, the trial showed a

The post Bayer gets FDA approval for prostate cancer drug Nubeqa appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply